On April 18, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its executive leaders will be providing an overview of the Company’s gene therapies for cancer and diabetes to investors and industry professionals at the following investor and industry conferences in April 2022 (Press release, Genprex, APR 18, 2022, View Source [SID1234612400]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event: NobleCon 18
Conference Dates: April 19-21, 2022
Presentation Date: Wednesday, April 20
Presentation Time: 11:30 a.m. ET
Location: Hard Rock Guitar Hotel, Hollywood, FL – Seminole Ballroom B
Presenter: Ryan Confer, Chief Financial Officer
A high-definition, video webcast of the presentation will be available the following day on the Company’s website at www.genprex.com and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek www.channelchek.com the investor portal created by Noble. The webcast will be archived on the company’s website, the NobleCon website and on Channelchek.com for a period of time following the event.
Event: Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mediterranean (Virtual)
Conference Dates: April 20-22, 2022
Virtual Presentation Date: Available on-demand within the virtual platform for all delegates to view starting April 20, 2022
Presenter: Mark Berger, Chief Medical Officer
This meeting will feature in-person and pre-recorded virtual presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering and broader regenerative medicine technologies.